FDA approves new ‘King Kong’ weight loss drug

Credit; Eli Lilly
Potential blockbuster dubbed Zepbound to join cousin drug Mounjaro on US market Tirzepatide, Eli Lilly’s GIP and GLP-1 agonist, described by media as “the King Kong of drugs”, has been approved for weight loss by the US Food and Drug Administration (FDA) under the brand name Zepbound. Similar to the way Novo Nordisk has marketed

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy researchers raise alarm on AI threat
Next Vale Peter Davoren Howard